Photo from wikipedia
Key Points Question Is use of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) associated with reduced risk of atrial fibrillation (AF) in older patients with type 2 diabetes? Findings In this US nationwide… Click to show full abstract
Key Points Question Is use of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) associated with reduced risk of atrial fibrillation (AF) in older patients with type 2 diabetes? Findings In this US nationwide cohort study assessing the risk of AF among more than 200 000 Medicare beneficiaries with type 2 diabetes, after propensity score matching, the initiation of SGLT-2is was associated with an 18% decrease in the risk of AF compared with dipeptidyl peptidase-4 inhibitors and a 10% decrease in the risk of AF compared with glucagon-like peptide-1 receptor agonists. Meaning These results provide substantive evidence supporting the potential benefits of initiation of an SGLT-2i in older adults with type 2 diabetes.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!